Transplacental flecainide therapy for fetal supraventricular tachycardia in a twin pregnancy.
We present the case of a twin pregnancy in which 1 fetus developed hydrops secondary to supraventricular tachycardia at 30 weeks' gestation. Transplacental flecainide administration successfully treated the condition without evidence of maternal or fetal side-effects. The case raises ethical and possibly legal issues that present when 1 fetus in a twin pregnancy develops a condition the management of which could cause complications to the other twin and/or the mother.
Edwards
A
A
Department of Obstetrics and Gynaecology, Canberra Clinical School, University of Sydney.
Peek
M J
MJ
Curren
J
J
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004200:Diseases in Twins / Q000628:therapy*; D004992:Ethics, Medical; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D005424:Flecainide / Q000627:therapeutic use*; D006801:Humans; D015160:Hydrops Fetalis / Q000000981:diagnostic imaging / Q000209:etiology; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000188:drug therapy*; D014463:Ultrasonography
D000889:Anti-Arrhythmia Agents; D005424:Flecainide